BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

Summary by AI BETAClose X

BioNTech announced positive Phase 2 results for trastuzumab pamirtecan in HER2-expressing, recurrent endometrial cancer, demonstrating clinically meaningful antitumor activity and a manageable safety profile. In centrally tested patients, the confirmed objective response rate was 47.9%, and median progression-free survival was 8.1 months, with similar outcomes observed in patients previously treated with checkpoint inhibitors and those with lower HER2 expression levels. These findings support the potential of trastuzumab pamirtecan, with a biologics license application planned for 2026.

Disclaimer*

UK 100

Latest directors dealings